Ion and tumor cell killing. Procedures We generated antigen-armed antibodies referred to as ATPPs, by coupling virus-derived MHC class I peptides to tumor-associated antigenspecific antibodies. Fluorescence resonance power transfer (FRET) was performed to demonstrate the supposed mode of action. T cell activation and tumor cell killing was assessed by quantification of interferon-gamma or lactate Fas Ligand (FasL) Proteins web dehydrogenase (LDH) release. Human PBMCs or expanded peptide-specific T cells have been utilized as effector cells for in vitro functionality assays and in vivo efficacy in MDAMB231 breast cancer